Click here to log in.
Search for therapies, clinical trials and demographic information by country and subtype.
Brentuximab Vedotin Shows Significant Clinical Activity in Phase III CTCL Trial
Based on the a higher frequency at relapse and evidence for clonal selection, TP53, FOXO1, MLL3, CCND3, NFKBIZ and STAT6 emerged as top candidate genes implicated in therapeutic resistance.
Results of a study suggest overactive IgE level from environmental exposures may provide insight into the progression of CLL.
Bertrand Liang of Pfenex addresses the state of the biosimilars industry, including key policy and drug pricing issues.
The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.